MDMG.L Regulatory News (MDMG)

Notice of H1 2013 IFRS results and management conference-call

September 4, 2013. Moscow, Russia. MD Medical Group Investments Plc ("MD Medical Group", "MDMG" or the "Company" - LSE: MDMG), Russia's leading provider of private women's and children's healthcare, announces that it will publish its financial results under international financial reporting standards ("IFRS") for the half-year ended June 30, 2013, on September 9, 2013.

MD Medical Group will host an H1 2013 IFRS results conference call on September 9, 2013, at 17:00 MSK (14:00 BST, 09:00 EST).

MD Medical will be represented by:

· Dr. Mark Kurtser, Chairman of the Board of Directors

· Dr. Elena Mladova, Chief Executive Officer

· Vitaly Ustimenko, Chief Financial Officer

· Alexander Rayt, Head of IFRS department

· Maxim Novikov, Head of IR

Conference-call details: Access Code:  4638933#

· Russia Toll Free: 8-495-580-9543

· UK Access Number: +44-(0)207-153-2027

· UK Toll Free: 0800-358-0886

· US Access Number: +1-480-629-9673

· US Toll-Free Number: +1-877-941-1469

The call will be held in English and will start with a 10-15 minute presentation followed by Q&A.

The replay of the call will be available until September 23, 2013.

Replay Numbers: Access Code: 4638933#

· UK + 44 (0)207 154 2833

· UK Toll Free 0800 358 3474

· US +1 303 590 3030

· US Toll Free +1-800-406-7325

The press-release and the consolidated financial statements will be available on the Company's website: http://www.mcclinics.com at about 10:00 MSK (07:00 BST, 02:00 EST).

The presentation for the Conference Call will be available on http://www.mcclinics.comstarting from 16:00 MSK (13:00 BST, 08:00 EST).

Please note that this call is only intended for Institutional Investors and sell-side Research

Analysts.

About MD Medical Group

MD Medical Group operates in the highly attractive Russian private healthcare service market and has a leading position in high-quality women's health and paediatrics. The company manages ten modern healthcare facilities, including two hospitals and eight outpatient clinics in Moscow, St. Petersburg, Ufa, Irkutsk and Perm. In addition, two franchised outpatient clinics operate in Kyiv.

The Company's main medical facilities are the Perinatal Medical Center (PMC), a 250-bed medical centre, which opened its doors in 2006, and Lapino hospital, a 182-bed medical centre, which opened at the end of 2012. In 2012, there were 3,253 deliveries in PMC and Lapino. The number of outpatient treatments for 2012 in PMC and the Company's outpatient clinics totalled 446,407. In March 2013, the Company began construction of its third hospital in Ufa. In April 2013 MD Medical Group completed the acquisition of the IDK Medical Company, a network of women's and children's health clinics located in the Russian region of Samara ("IDK"). In May 2013, the Company acquired Mother&Child clinic in Irkutsk, which previously has operated through a franchise agreement with MD Medical Group.

The Company's shares have been listed on the London Stock Exchange (LSE ticker "MDMG") in the form of Global Depositary Receipts (GDRs) since 12 October 2012.

* * *

Forward-Looking Statements:

This press release contains forward looking statements, which are based on the Company's current expectations and assumptions and may involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. The forward looking statements contained in this press release are based on past trends or activities and should not be taken that such trends or activities will continue in the future. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a number of variables which could cause actual results or trends to differ materially, including, but not limited to: conditions in the market, market position of the Company, earnings, financial position, cash flows, return on capital and operating margins, anticipated investments and economic conditions; the Company's ability to obtain capital/additional finance; a reduction in demand by customers; an increase in competition; an unexpected decline in revenue or profitability; legislative, fiscal and regulatory developments, including, but not limited to, changes in environmental and health and safety regulations; exchange rate fluctuations; retention of senior management; the maintenance of labour relations; fluctuations in the cost of input costs; and operating and financial restrictions as a result of financing arrangements.

No statement in this press release is intended to constitute a profit forecast, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for the Company. Each forward looking statement relates only as of the date of the particular statement.